1. Favorable prognostic impact of RAS mutation status in multiple myeloma treated with high-dose melphalan and autologous stem cell support in the era of novel agents: a single center perspective. Issue 1 (2nd January 2016) Authors: Gebauer, Niklas; Biersack, Harald; Czerwinska, Ann-Cathrin; Schemme, Janina; Hardel, Tim Tristan; Bernard, Veronica; Rades, Dirk; Lehnert, Hendrik; Luley, Kim Barbara; Thorns, Christoph Journal: Leukemia & lymphoma Issue: Volume 57:Issue 1(2016:Jan.) Page Start: 226 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Issue 12 (December 2016) Authors: Al-Batran, Salah-Eddin; Hofheinz, Ralf D; Pauligk, Claudia; Kopp, Hans-Georg; Haag, Georg Martin; Luley, Kim Barbara; Meiler, Johannes; Homann, Nils; Lorenzen, Sylvie; Schmalenberg, Harald; Probst, Stephan; Koenigsmann, Michael; Egger, Matthias; Prasnikar, Nicole; Caca, Karel; Trojan, Jörg; Marte... Journal: Lancet oncology Issue: Volume 17:Issue 12(2016:Dec.) Page Start: 1697 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Phase III randomized, double‐blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum‐containing regimen (RADPAC). Issue 9 (7th May 2020) Authors: Lorenzen, Sylvie; Knorrenschild, Jorge Riera; Pauligk, Claudia; Hegewisch‐Becker, Susanna; Seraphin, Jörg; Thuss‐Patience, Peter; Kopp, Hans‐Georg; Dechow, Tobias; Vogel, Arndt; Luley, Kim Barbara; Pink, Daniel; Stahl, Michael; Kullmann, Frank; Hebart, Holger; Siveke, Jens; Egger, Matthias; Homan... Journal: International journal of cancer Issue: Volume 147:Issue 9(2020) Page Start: 2493 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Single nucleotide polymorphisms in TP53 but not KRAS or MDM2 are predictive of clinical outcome in multiple myeloma treated with high-dose melphalan and autologous stem cell support. Issue 6 (2nd June 2016) Authors: Gebauer, Niklas; Biersack, Harald; Czerwinska, Ann-Cathrin; Schemme, Janina; Hardel, Tim Tristan; Bernard, Veronica; Rades, Dirk; Lehnert, Hendrik; Luley, Kim Barbara; Thorns, Christoph Journal: Leukemia & lymphoma Issue: Volume 57:Issue 6(2016:Jun.) Page Start: 1482 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗